Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Presentations from EuHEA 2018
2 August 2018
OHE staff recently attended the European Health Economics Association (EuHEA) 2018 conference. In this blog post, we share a selection of our presentations. Establishing a Reasonable…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
To what extent can R&D incentives, competition and other factors facilitate access to highly valuable and costly pharmaceutical innovations?
Presentations from AES and PROMs Summer 2018
24 July 2018
OHE staff recently attended AES and PROMs Summer 2018 conferences. In this blog post, we share a selection of our presentations.
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
What would be the price for an orphan drug that generate rates of return no greater/smaller than the industry average? Is it reasonable?
OHE at EuHEA 2018
10 July 2018
Meet some of the OHE team at the European Health Economics Association (EuHEA) 2018 conference in Maastricht, 11-14 July.
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.
OHE at HESG, AES and PROMs Summer 2018
15 June 2018
Meet some of the OHE team at any of three conferences taking place from 20-22 June: HESG, AES, and the PROMS Research Conference.
A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List
19 May 2018
OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.
Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
15 May 2018
OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.